|
|
Blood, Vol. 108, Issue 6, 1991-1998, September 15, 2006
Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation
Blood Shen et al.
108: 1991
Supplemental materials for: Shen et al
Files in this Data Supplement:
- Supplemental Methods (PDF, 31.8 KB)
- Table S1. Bone marrow B cell development (PDF, 17.6 KB) -
Cells were stained with Abs to B220, IgM, and CD21. Percentages listed are for viable IgM+B220+ cells. T1 and T2, transitional 1 and 2 B cells. Data represent mean ± SD from 3 mice.
- Table S2. Necropsy and tumor diagnoses for TCL1-tg mice (PDF, 20.3 KB) -
TCL1-tg mice are listed in order by age in months at which they became moribund and were sacrificed. The diagnosis is established for 10 of 19 mice evaluated during the first 20 months of study using a combination of morphologic, clonality, flow cytometric, and immunohistochemical techniques applied to Mouse Models of Human Cancer Consortium (MMHCC) criteria.6 Importantly, CD5 is not a critical marker for B1 B cells as it relates to mouse lymphomas as >85% of mouse lymphoid tumors are positive whether they originate from the marginal zone or are germinal center-derived.7 Samples below the dashed line are from TCL1-tg mice that did not appear moribund at 20 months and were sacrificed and examined or from various control mice that remained healthy in appearance. ND, not determined; BLL, Burkitt-like lymphoma; FBL, follicular B cell lymphoma; DLBCL, diffuse large B cell lymphoma; IB, immunoblastic; HA, histiocyte-associated; HS, histiocytic sarcoma.
- Table S3. MYC mutations in TCL1-tg B cell lymphomas (PDF, 17.1 KB)
| |
